
OLK
Healthcare · Diagnostics & Research · $3.24B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2024
EPS trend, 90 days to now · -8.3% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 13, 2024 | Before the open | -0.15 | -0.13 | +13.3% |
| Mar 25, 2024 | Before the open | 0.15 | -0.06 | -140.0% |
| Nov 15, 2023 | Before the open | -0.08 | -0.01 | +87.5% |
| Aug 9, 2023 | Before the open | -0.10 | -0.07 | +30.0% |
| May 11, 2023 | Before the open | -0.12 | -0.11 | +8.3% |
| Feb 21, 2023 | Before the open | 0.01 | 0.05 | +400.0% |
| Nov 10, 2022 | Before the open | -0.09 | -0.01 | +88.9% |
| Aug 11, 2022 | Before the open | -0.14 | -0.04 | +71.4% |
| May 12, 2022 | Before the open | -0.16 | -0.10 | +37.5% |
| Feb 14, 2022 | Before the open | 0.03 | -0.07 | -333.3% |
| Nov 10, 2021 | Before the open | -0.05 | -0.05 | 0.0% |
| Aug 11, 2021 | Before the open | -0.07 | -0.09 | -28.6% |
| May 20, 2021 | Before the open | -0.11 | -0.48 |
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases;…
| -336.4% |
| Mar 26, 2021 | After the close | 0.00 | 0.17 | — |